{"log_id": 7267609771890936995, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0.019055, "average": 0.939386, "min": 0.425516}, "location": {"width": 958, "top": 169, "height": 35, "left": 122}, "words": "用时可能需要减少瑞格列的用药剂量。在同一研究中,瑞格列奈与吉非贝齐和CYP3A4制剂伊曲康唑"}, {"probability": {"variance": 0.004264, "average": 0.972598, "min": 0.689011}, "location": {"width": 831, "top": 217, "height": 30, "left": 120}, "words": "合用显示出更强的降糖作用,瑞格列奈AUC增加19.4倍,半衰期从1.3小时延长到6.1小时"}, {"probability": {"variance": 0.003781, "average": 0.968304, "min": 0.647651}, "location": {"width": 919, "top": 262, "height": 36, "left": 158}, "words": "甲氧苄啶(每日两次,每次160mg)是一种弱CYP2C8抑制剂,与瑞格列奈(单剂0.25mg)同服,可"}, {"probability": {"variance": 0.005874, "average": 0.96889, "min": 0.63757}, "location": {"width": 957, "top": 309, "height": 34, "left": 118}, "words": "使瑞格列奈 AUC, Cmas和生物半衰期有轻微的增加(分别为1.6倍,1.4倍和1.2倍),血糖水平增加无明显"}, {"probability": {"variance": 0.005452, "average": 0.972101, "min": 0.648773}, "location": {"width": 958, "top": 355, "height": 35, "left": 117}, "words": "的统计学差异。这些缺少药效学结果的数据系根据瑞格列奈低剂治疗获得。由于尚无瑞格列奈剂高于"}, {"probability": {"variance": 0.008334, "average": 0.959242, "min": 0.480371}, "location": {"width": 963, "top": 402, "height": 35, "left": 112}, "words": "025mg与甲氧啶剂量高于320rug的合用安全性数据,因此应避免将瑞格列奈与甲氧苄氨嘧啶合用。如果"}, {"probability": {"variance": 4.7e-05, "average": 0.996323, "min": 0.970481}, "location": {"width": 581, "top": 450, "height": 28, "left": 115}, "words": "必须合用,应严密监测患者的血糖水平,并进行严密的临床监测"}, {"probability": {"variance": 0.003369, "average": 0.982797, "min": 0.598933}, "location": {"width": 919, "top": 495, "height": 34, "left": 155}, "words": "利福平是一种CYP3A4强诱导剂,也是CYP2C8诱导剂,在瑞格列奈的代谢过程中同时起诱导和抑制"}, {"probability": {"variance": 0.010367, "average": 0.949016, "min": 0.521712}, "location": {"width": 960, "top": 541, "height": 34, "left": 112}, "words": "作用。使用利福平(600mg)先期治疗7大,然后与瑞格列奈(单剂4m)在第7天时合用,AUC降低了"}, {"probability": {"variance": 0.013138, "average": 0.952357, "min": 0.412743}, "location": {"width": 957, "top": 586, "height": 36, "left": 113}, "words": "50%(这是诱导和制作用的共同结果),在最后一次服用利福平24小时后服用瑞格列奈,瑞格列的AUC"}, {"probability": {"variance": 0.001916, "average": 0.97334, "min": 0.867873}, "location": {"width": 248, "top": 634, "height": 26, "left": 111}, "words": "降低了80%(单独诱导作用"}, {"probability": {"variance": 0.005642, "average": 0.974688, "min": 0.535941}, "location": {"width": 917, "top": 679, "height": 36, "left": 152}, "words": "利福平与瑞格列奈合用可能会降低瑞格列的用药剂,应严密监测患者在开始使用利福平(快速排"}, {"probability": {"variance": 0.004919, "average": 0.973342, "min": 0.558567}, "location": {"width": 958, "top": 727, "height": 34, "left": 110}, "words": "制》增加剂量(混合抑制和诱导)和停用利福平(单独诱导)以及停用利福平约1周后,其诱导作用消失"}, {"probability": {"variance": 0.008334, "average": 0.96455, "min": 0.576085}, "location": {"width": 511, "top": 775, "height": 27, "left": 110}, "words": "时的血糖水平,并根据血糖水平调节瑞格列奈的使用剂"}, {"probability": {"variance": 0.013977, "average": 0.945615, "min": 0.49167}, "location": {"width": 812, "top": 821, "height": 35, "left": 151}, "words": "克拉霉素足一种CYP3A4强抑制剂,以每日两次,每次250mg剂量与瑞格列奈(单剂0.25"}, {"probability": {"variance": 0, "average": 0.99578, "min": 0.99578}, "location": {"width": 41, "top": 830, "height": 24, "left": 1013}, "words": "同"}, {"probability": {"variance": 0.014758, "average": 0.937345, "min": 0.355609}, "location": {"width": 957, "top": 868, "height": 35, "left": 109}, "words": "使瑞格列的暴露量有微弱的增加(AUC增加14倍,Ca增加1.7倍),血清胰岛素AUC平均增加1.5"}, {"probability": {"variance": 0.003731, "average": 0.959076, "min": 0.820648}, "location": {"width": 196, "top": 916, "height": 24, "left": 107}, "words": "倍(C增加1.6倍)"}, {"probability": {"variance": 0.007082, "average": 0.966095, "min": 0.493041}, "location": {"width": 718, "top": 962, "height": 33, "left": 145}, "words": "服用瑞格列奈(单次给药4mg)的同时服用CYP3A4强抑制剂酮康唑(每日200"}, {"probability": {"variance": 7.4e-05, "average": 0.994509, "min": 0.974549}, "location": {"width": 144, "top": 968, "height": 26, "left": 922}, "words": "可在一定范围内"}, {"probability": {"variance": 0.004423, "average": 0.975583, "min": 0.622087}, "location": {"width": 725, "top": 1010, "height": 33, "left": 107}, "words": "增加瑞格列奈的暴露量(AUC增加1.2倍,Cm增加1.6倍),血糖变化低于8%"}, {"probability": {"variance": 0.003265, "average": 0.970051, "min": 0.709719}, "location": {"width": 524, "top": 1059, "height": 26, "left": 145}, "words": "瑞格列奈与西米替丁、硝苯地平或辛伐他汀合用,所有C"}, {"probability": {"variance": 0.021622, "average": 0.887446, "min": 0.597932}, "location": {"width": 289, "top": 1062, "height": 30, "left": 775}, "words": "底物均来显著改变瑞格列的约"}, {"probability": {"variance": 2e-06, "average": 0.998578, "min": 0.995292}, "location": {"width": 123, "top": 1106, "height": 24, "left": 104}, "words": "代动力学参数"}, {"probability": {"variance": 0.003108, "average": 0.972396, "min": 0.784336}, "location": {"width": 920, "top": 1152, "height": 30, "left": 143}, "words": "在健康志愿者中进行的药物相互作用研究发现,瑞格列奈对地高辛、茶碱和法华林的药代动力学特性"}, {"probability": {"variance": 0.00766, "average": 0.976581, "min": 0.520575}, "location": {"width": 656, "top": 1199, "height": 34, "left": 103}, "words": "无影响。因此在与瑞格列奈联合使用时,无需调整这些药物的剂量"}, {"probability": {"variance": 0.00981, "average": 0.962771, "min": 0.523055}, "location": {"width": 918, "top": 1244, "height": 36, "left": 144}, "words": "在健康志愿者中开展的一项药代动力学研究表明,合用口服避孕药(乙炔雌二醇1左炔诺孕酮)虽然会"}, {"probability": {"variance": 0.004462, "average": 0.972257, "min": 0.607765}, "location": {"width": 962, "top": 1294, "height": 32, "left": 99}, "words": "缩短瑞格列奈的达峰时间,但不会改变瑞格列奈的总生物利用度至相关临床范围。瑞格列奈对左炔诺孕酮"}, {"probability": {"variance": 0.001214, "average": 0.990234, "min": 0.788789}, "location": {"width": 769, "top": 1340, "height": 33, "left": 101}, "words": "的生物利用度没有具临床意义的影响,但不能排除对乙炔雌二醇的生物利用度的影响"}, {"probability": {"variance": 0.014198, "average": 0.949758, "min": 0.477209}, "location": {"width": 465, "top": 1389, "height": 27, "left": 143}, "words": "卜列药物可能增强和或延长瑞格列奈的降血糖作用"}, {"probability": {"variance": 0.005734, "average": 0.975029, "min": 0.602431}, "location": {"width": 898, "top": 1437, "height": 30, "left": 141}, "words": "古非贝齐,克拉霉索,酮康唑,伊曲康唑,甲氧苄啶,其他类型抗糖尿病药物,单胺氧化酶抑制剂(MAO"}, {"probability": {"variance": 0.000366, "average": 0.987391, "min": 0.914055}, "location": {"width": 809, "top": 1483, "height": 33, "left": 100}, "words": "非选择性β受体阻滞剂,血管紧张素转换酶(ACE)抑制剂,酒精以及促合成代谢的激素"}, {"probability": {"variance": 0.004164, "average": 0.974558, "min": 0.742858}, "location": {"width": 372, "top": 1531, "height": 27, "left": 144}, "words": "下列药物可能诚弱瑞格列奈的降血糖作用"}], "language": 3}